INITIAL RESULTS FROM A PHASE 2 STUDY OF CARFILZOMIB, LENALIDOMIDE, AND LOW-DOSE DEXAMETHASONE (KRD) PLUS AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT) IN NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM)
EHA Library, Andrzej J. Jakubowiak,
53793
RICOLINOSTAT (ACY-1215), THE FIRST SELECTIVE HISTONE DEACETYLASE 6 INHIBITOR, IS ACTIVE AND WELL TOLDERATED IN COMBINATION WITH LENALIDOMIDE OR BORTEZOMIB IN PATIENTS WITH REFRACTORY MYELOMA
EHA Library, Noopur Raje,
53804
PRELIMINARY SAFETY AND EFFICACY OF TH-302, AN INVESTIGATIONAL HYPOXIA-TARGETED DRUG, AND DEXAMETHASONE (DEX) IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RR MM)
EHA Library, PAUL RICHARDSON,
53806
PERSISTENT PFS BENEFIT AND SUPERIOR PFS2 WITH VTD VS TD FOR NEWLY DIAGNOSED, TRANSPLANT ELIGIBLE, MULTIPLE MYELOMA (MM) PATIENTS: UPDATED ANALYSIS OF GIMEMA MMY-3006 STUDY
EHA Library, Michele Cavo,
53808
Long-term follow-up of a randomized phase 2 study of bortezomib, thalidomide, and dexamethasone, with or without cyclophosphamide, as induction therapy for patients with previously untreated multiple myeloma
EHA Library, Heinz Ludwig,
53815
LOSS OF BCL2L12 PROTEIN EXPRESSION PREDICTS RELAPSE IN PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA TREATED WITH RITUXIMAB PLUS CONVENTIONAL CHEMOTHERAPY (CYCLOPHOSPHAMIDE, DOXORUBICIN, VINCRISTINE, AN
EHA Library, Sotirios Papageorgiou,
53872
PRECLINICAL EVALUATION OF A NOVEL, HIGHLY POTENT AND SELECTIVE PI3K-DELTA INHIBITOR, CPL-302-201, FOR THE TREATMENT OF HEMATOLOGIC MALIGNANCIES
EHA Library, Aleksandra Stanczak,
53878
BRIEF RITUXIMAB, BENDAMUSTINE, MITOXANTRONE (R-BM) INDUCTION PLUS RITUXIMAB CONSOLIDATION IN ELDERLY DE NOVO ADVANCED STAGE FOLLICULAR LYMPHOMA: FINAL RESULTS OF A STUDY BY FONDAZIONE ITALIANA LINFOMI
EHA Library, Carola Boccomini,
53884